Join Growin Stock Community!

Lexaria bioscience corp.LEXX.US Overview

US StockHealthcare
(No presentation for LEXX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

LEXX AI Insights

LEXX Overall Performance

LEXX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

LEXX Recent Performance

-3.85%

Lexaria bioscience corp.

0.05%

Avg of Sector

-0.31%

S&P500

LEXX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

LEXX Key Information

LEXX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

LEXX Profile

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Price of LEXX

LEXX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

LEXX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.56
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
33.33
PB Ratio
3.54
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-2067.65%
Revenue Growth (YoY)
5.05%
Profit Growth (YoY)
5.62%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.56
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
33.33
PB Ratio
3.54
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-2067.65%
Revenue Growth (YoY)
5.05%
Profit Growth (YoY)
5.62%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is LEXX's latest earnings report released?

    The most recent financial report for Lexaria bioscience corp. (LEXX) covers the period of 2026Q1 and was published on 2025/11/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LEXX's short-term business performance and financial health. For the latest updates on LEXX's earnings releases, visit this page regularly.

  • How is LEXX's revenue growth?

    In the latest financial report, Lexaria bioscience corp. (LEXX) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does LEXX have?

    As of the end of the reporting period, Lexaria bioscience corp. (LEXX) had total debt of 101.92K, with a debt ratio of 0.02. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does LEXX have?

    At the end of the period, Lexaria bioscience corp. (LEXX) held Total Cash and Cash Equivalents of 4.28M, accounting for 0.71 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is LEXX's EPS continuing to grow?

    According to the past four quarterly reports, Lexaria bioscience corp. (LEXX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.07. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of LEXX?

    Lexaria bioscience corp. (LEXX)'s Free Cash Flow (FCF) for the period is -984.1K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 64.22% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of LEXX?

    The latest valuation data shows Lexaria bioscience corp. (LEXX) has a Price-To-Earnings (PE) ratio of -1.87 and a Price/Earnings-To-Growth (PEG) ratio of 0.08. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.